Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.
Federica Miglietta(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Angelo Paolo Dei Tos(University of Padua), Andrea Vingiani(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Botticelli(Policlinico Umberto I), Valentina Guarneri(Istituto Oncologico Veneto), Francesca Porra(University of Padua), Matteo Fassan(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Marleen Kok(The Netherlands Cancer Institute), Giancarlo Pruneri(University of Milan), Giuseppe Fotia, Gaia Griguolo(University of North Carolina at Chapel Hill), Fabio Secomandi(University of Modena and Reggio Emilia), Matilde Cacciatore(Ca' Foncello Hospital), Manon de Graaf(Dutch Cancer Society), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Valerio Pellegrini(University of Padua), Daniela Iannaccone(University of Padua)
Cited by 1
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k